Latest & greatest articles for calcium

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on calcium or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on calcium and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for calcium

81. Electrophysiological properties and calcium handling of embryonic stem cell-derived cardiomyocytes Full Text available with Trip Pro

Electrophysiological properties and calcium handling of embryonic stem cell-derived cardiomyocytes Embryonic stem cell-derived cardiomyocytes (ESC-CMs) hold great interest in many fields of research including clinical applications such as stem cell and gene therapy for cardiac repair or regeneration. ESC-CMs are also used as a platform tool for pharmacological tests or for investigations of cardiac remodeling. ESC-CMs have many different aspects of morphology, electrophysiology, calcium

2016 Integrative medicine research

82. Prognostic Value of Coronary Artery Calcium Score in Acute Chest Pain Patients Without Known Coronary Artery Disease: Systematic Review and Meta-analysis

Prognostic Value of Coronary Artery Calcium Score in Acute Chest Pain Patients Without Known Coronary Artery Disease: Systematic Review and Meta-analysis Prognostic Value of Coronary Artery Calcium Score in Acute Chest Pain Patients Without Known Coronary Artery Disease: Systematic Review and Meta-analysis Kongkiat Chaikriangkrai, MD; Ghanshyam Palamaner Subash Shantha, MD; Hye Yeon Jhun, MD; Patompong Ungprasert, MD; Gardar Sigurdsson, MD; Faisal Nabi, MD; John J. Mahmarian, MD; Su Min Chang (...) , MD* *Corresponding Author. E-mail: smchang@houstonmethodist.org. Study objective: Coronary artery calcium score (CACS) is a well-established test for risk stratifying asymptomatic patients.RecentstudiesalsoindicatethatCACSmayaccuratelyriskstratifystablepatientspresentingtotheemergency department (ED) with acute chest pain; however, many were underpowered. The purpose of this systematic review and meta-analysis is to evaluate the prognostic value and accuracy of a zero (normal) CACS

2016 Annals of Emergency Medicine Systematic Review Snapshots

83. 10-Year Coronary Heart Disease Risk Prediction Using Coronary Artery Calcium and Traditional Risk Factors: Derivation in the MESA (Multi-Ethnic Study of Atherosclerosis) With Validation in the HNR (Heinz Nixdorf Recall) Study and the DHS (Dallas Heart Stu Full Text available with Trip Pro

10-Year Coronary Heart Disease Risk Prediction Using Coronary Artery Calcium and Traditional Risk Factors: Derivation in the MESA (Multi-Ethnic Study of Atherosclerosis) With Validation in the HNR (Heinz Nixdorf Recall) Study and the DHS (Dallas Heart Stu Several studies have demonstrated the tremendous potential of using coronary artery calcium (CAC) in addition to traditional risk factors for coronary heart disease (CHD) risk prediction. However, to date, no risk score incorporating CAC has

2015 EvidenceUpdates

84. Efficacy of nanocrystalline bone substitute biphasic calcium phosphate/poly-DL-lactide-co-glycolide for periodontal intrabony defects filling. (Abstract)

Efficacy of nanocrystalline bone substitute biphasic calcium phosphate/poly-DL-lactide-co-glycolide for periodontal intrabony defects filling. Different bone substitutes have been used for filling and reparation of intrabony defects. The aim of this study was to compare nanocrystalline material, biphasic calcium phosphate poly-DL-lactide-co-glycolide (BCP/PLGA) with deproteinised bovine bone (DPBB) and beta-tricalcium phosphate (P-TCP) in the treatment of periodontal intrabony defects.The study

2015 Vojnosanitetski pregled Controlled trial quality: uncertain

85. A Trial of Calcium and Vitamin D for the Prevention of Colorectal Adenomas. Full Text available with Trip Pro

A Trial of Calcium and Vitamin D for the Prevention of Colorectal Adenomas. Epidemiologic and preclinical data suggest that higher intake and serum levels of vitamin D and higher intake of calcium reduce the risk of colorectal neoplasia. To further study the chemopreventive potential of these nutrients, we conducted a randomized, double-blind, placebo-controlled trial of supplementation with vitamin D, calcium, or both for the prevention of colorectal adenomas.We recruited patients (...) with recently diagnosed adenomas and no known colorectal polyps remaining after complete colonoscopy. We randomly assigned 2259 participants to receive daily vitamin D3 (1000 IU), calcium as carbonate (1200 mg), both, or neither in a partial 2×2 factorial design. Women could elect to receive calcium plus random assignment to vitamin D or placebo. Follow-up colonoscopy was anticipated to be performed 3 or 5 years after the baseline examinations, according to the endoscopist's recommendation. The primary end

2015 NEJM Controlled trial quality: predicted high

86. Calcium channel blockers for pulmonary arterial hypertension. (Abstract)

Calcium channel blockers for pulmonary arterial hypertension. Pulmonary arterial hypertension (PAH) is one of several forms of pulmonary hypertension: a chronic disease of the pulmonary vasculature. The mean age at diagnosis is around 50 years old, with increasing prevalence in people over 70 years old (10% to 17%). The median survival to be approximately seven years with one-, three-, five-, and seven-year survival rates from time of diagnostic right-sided heart catheterization were 85%, 68 (...) %, 57%, and 49%, respectively. Several studies showed that calcium channel blockers (CCBs) reduce right ventricular hypertrophy and improve long-term haemodynamics in PAH.To evaluate the clinical efficacy and harms of CCBs for people with PAH.The search strategy was provided by the Cochrane Airways Group Trials Search Co-ordinator. The following databases were searched from their inception until September 2014: the Cochrane Airways Group Register of Trials (CAGR); the Cochrane Central Register

2015 Cochrane

87. Is Shock Index a Valid Predictor of Mortality in Emergency Department Patients With Hypertension, Diabetes, High Age, or Receipt of beta- or Calcium Channel Blockers? (Abstract)

Is Shock Index a Valid Predictor of Mortality in Emergency Department Patients With Hypertension, Diabetes, High Age, or Receipt of beta- or Calcium Channel Blockers? Shock index is a widely reported tool to identify patients at risk for circulatory collapse. We hypothesize that old age, diabetes, hypertension, and β- or calcium channel blockers weaken the association between shock index and mortality.This was a cohort study of all first-time emergency department (ED) visits between 1995 (...) and 2011 (n=111,019). We examined whether age 65 years or older, diabetes, hypertension, and use of β- or calcium channel blockers modified the association between shock index and 30-day mortality.The 30-day mortality was 3.0%. For all patients, with shock index less than 0.7 as reference, a shock index of 0.7 to 1 had an adjusted odds ratio (OR) of 2.9 (95% confidence interval [CI] 2.7 to 3.2) for 30-day mortality, whereas shock index greater than or equal to 1 had an OR of 10.5 (95% CI 9.3 to 11.7

2015 EvidenceUpdates

88. Calcium supplementation for prevention of primary hypertension. Full Text available with Trip Pro

Calcium supplementation for prevention of primary hypertension. Hypertension is a major public health problem that increases the risk of cardiovascular and kidney diseases. Several studies have shown an inverse association between calcium intake and blood pressure. As small reductions in blood pressure have been shown to produce rapid reductions in vascular disease risk even in individuals with normal blood pressure ranges, this review intends to evaluate the effect of calcium supplementation (...) in normotensive individuals as a preventive health measure.To assess the efficacy and safety of calcium supplementation versus placebo or control for reducing blood pressure in normotensive people.We searched the Cochrane Hypertension Group Specialised Register, the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, MEDLINE In-Process, EMBASE and ClinicalTrials.gov for randomised controlled trials up to October 2014. The WHO International Clinical Trials Registry Platform (ICTRP) is searched

2015 Cochrane

89. Vitamin D and Calcium Attenuate Bone Loss With Antiretroviral Therapy Initiation: A Randomized Trial. Full Text available with Trip Pro

Vitamin D and Calcium Attenuate Bone Loss With Antiretroviral Therapy Initiation: A Randomized Trial. Antiretroviral therapy initiation for HIV-1 infection is associated with 2% to 6% loss of bone mineral density (BMD).To evaluate the effect of vitamin D3 plus calcium supplementation on bone loss associated with antiretroviral therapy initiation.48-week prospective, randomized, double-blind, placebo-controlled study. (ClinicalTrials.gov: NCT01403051).39 AIDS Clinical Trials Group units.Adults (...) with antiretroviral therapy-naive HIV.BMD by dual-energy x-ray absorptiometry, 25-hydroxyvitamin D levels, and other laboratory assessments.165 eligible patients were randomly assigned (79 received vitamin D3 plus calcium and 86 received placebo). The study groups were well-balanced at baseline: 90% were men, 33% were non-Hispanic black, and the median CD4 count was 0.341 × 109 cells/L. At 48 weeks, the percentage of decline in total hip BMD was smaller in the vitamin D3 plus calcium group than in the placebo

2015 Annals of Internal Medicine Controlled trial quality: predicted high

90. Long-term Use of Acamprosate Calcium for Alcoholism

Long-term Use of Acamprosate Calcium for Alcoholism Disclaimer: The Rapid Response Service is an information service for those involved in planning and providing health care in Canada. Rapid responses are based on a limited literature search and are not comprehensive, systematic reviews. The intent is to provide a list of sources of the best evidence on the topic that CADTH could identify using all reasonable efforts within the time allowed. Rapid responses should be considered along with other (...) not be copied, posted on a web site, redistributed by email or stored on an electronic system without the prior written permission of CADTH or applicable copyright owner. Links: This report may contain links to other information available on the websites of third parties on the Internet. CADTH does not have control over the content of such sites. Use of third party sites is governed by the owners? own terms and conditions. TITLE: Long-term Use of Acamprosate Calcium for Alcoholism: A Review of the Clinical

2015 Canadian Agency for Drugs and Technologies in Health - Rapid Review

91. High-Protein Diet Without Increased Calcium Intake Can Lead to Ridge Resorption and Osteoporosis in Women

High-Protein Diet Without Increased Calcium Intake Can Lead to Ridge Resorption and Osteoporosis in Women UTCAT2893, Found CAT view, CRITICALLY APPRAISED TOPICs University: | | ORAL HEALTH EVIDENCE-BASED PRACTICE PROGRAM View the CAT / Title High-Protein Diet Without Increased Calcium Intake Can Lead to Ridge Resorption and Osteoporosis in Women Clinical Question How does a high protein diet affect ridge resorption in women? Clinical Bottom Line A high protein diet coupled with a low calcium (...) intake can increase urinary losses of calcium and is linked to osteoporosis and ridge resorption in older women. This is supported by narrative reviews outlining observations of populations who maintain a high protein diet and a narrative review of studies showing the relationship between increased protein intake and increased levels of calcium lost in urine. Best Evidence (you may view more info by clicking on the PubMed ID link) PubMed ID Author / Year Patient Group Study type (level of evidence

2015 UTHSCSA Dental School CAT Library

92. Additive Prognostic Value of Coronary Artery Calcium Score Over Coronary Computed Tomographic Angiography Stenosis Assessment in Symptomatic Patients Without Known Coronary Artery Disease (Abstract)

Additive Prognostic Value of Coronary Artery Calcium Score Over Coronary Computed Tomographic Angiography Stenosis Assessment in Symptomatic Patients Without Known Coronary Artery Disease The objective of this study was to examine the additive prognostic performance of coronary artery calcium score (CACS) over coronary computed tomography angiography (CCTA) stenosis assessment in symptomatic patients suspected for coronary artery disease (CAD) undergoing CCTA. A total of 805 symptomatic

2015 EvidenceUpdates

93. Randomised controlled trial: ?-channel and calcium-channel blockers are ineffective as medical expulsive therapy for ureteral stones regardless of size and location

Randomised controlled trial: ?-channel and calcium-channel blockers are ineffective as medical expulsive therapy for ureteral stones regardless of size and location α-channel and calcium-channel blockers are ineffective as medical expulsive therapy for ureteral stones regardless of size and location | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more (...) about how we use cookies, please see our . Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here α-channel and calcium-channel blockers are ineffective as medical expulsive therapy

2015 Evidence-Based Medicine

94. Natpara (parathyroid horomone) - To control hypocalcemia (low blood calcium levels) in patients with hypoparathyroidism

Natpara (parathyroid horomone) - To control hypocalcemia (low blood calcium levels) in patients with hypoparathyroidism Drug Approval Package: Brand Name (Generic Name) NDA # Drug Approval Package U.S. Food & Drug Administration Search FDA Drug Approval Package - Natpara (parathyroid hormone) Company: NPS Pharmaceuticals Inc. Application No.: 125511 Approval Date: 1/23/2015 Persons with disabilities having problems accessing the PDF files below may call (301) 796-3634 for assistance. (PDF) (PDF

2015 FDA - Drug Approval Package

95. Vitamin D and calcium: a systematic review of health outcomes (update)

Vitamin D and calcium: a systematic review of health outcomes (update) Vitamin D and calcium: a systematic review of health outcomes (update) Vitamin D and calcium: a systematic review of health outcomes (update) Newberry SJ, Chung M, Shekelle PG, Booth MS, Liu JL, Maher AR, Motala A, Cui M, Perry T Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database (...) . Citation Newberry SJ, Chung M, Shekelle PG, Booth MS, Liu JL, Maher AR, Motala A, Cui M, Perry T. Vitamin D and calcium: a systematic review of health outcomes (update) Rockville: Agency for Healthcare Research and Quality (AHRQ). Evidence Report/Technology Assessment No. 217. 2014 Authors' objectives To systematically summarize the evidence on the relationship between vitamin D alone or in combination with calcium on selected health outcomes included in the earlier review: primarily those related

2014 Health Technology Assessment (HTA) Database.

96. Dioctyl Sulfosuccinate or Docusate (Calcium or Sodium) for the Prevention or Management of Constipation

Dioctyl Sulfosuccinate or Docusate (Calcium or Sodium) for the Prevention or Management of Constipation TITLE: Dioctyl Sulfosuccinate or Docusate (Calcium or Sodium) for the Prevention or Management of Constipation: A Review of the Clinical Effectiveness DATE: 26 June 2014 CONTEXT AND POLICY ISSUES Constipation has many definitions and is often described differently depending on the population queried. Many physicians define constipation as a reduction in the frequency of bowel movements (...) or bulking agents (i.e. psyllium seed husk), osmotic laxatives (i.e. lactulose, sorbitol, polyethylene glycol [PEG]), stimulant laxatives (i.e. sennosides, bisacodyl, sodium picosulfate), and stool softeners (i.e. docusate sodium or calcium). 1,2 In North America, docusate and a stimulant laxative such as sennosides are commonly used in bowel treatment protocols associated with institutionalized elderly 4 and oncology treatments. 5 A paucity of evidence is available to support the use of the stool

2014 Canadian Agency for Drugs and Technologies in Health - Rapid Review

97. Vitamin D treatment in calcium-deficiency rickets: a randomised controlled trial Full Text available with Trip Pro

Vitamin D treatment in calcium-deficiency rickets: a randomised controlled trial To determine whether children with calcium-deficiency rickets have a better response to treatment with vitamin D and calcium than with calcium alone.Randomised controlled trial.Jos University Teaching Hospital, Jos, Nigeria.Nigerian children with active rickets treated with calcium carbonate as limestone (approximately 938 mg elemental calcium twice daily) were, in addition, randomised to receive either oral (...) (56.4±17.2 nmol/L) than in those who did not (37.7±18.5 nmol/L, p<0.001).In children with calcium-deficiency rickets, there is a trend for vitamin D to improve the response to treatment with calcium carbonate as limestone, independent of baseline 25(OH)D concentrations.ClinicalTrials.gov NCT00949832.Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.

2014 EvidenceUpdates Controlled trial quality: predicted high

98. Fortification of Juices with Calcium Helps Decrease the Risk of Dental Erosion

Fortification of Juices with Calcium Helps Decrease the Risk of Dental Erosion UTCAT2663, Found CAT view, CRITICALLY APPRAISED TOPICs University: | | ORAL HEALTH EVIDENCE-BASED PRACTICE PROGRAM View the CAT / Title Fortification of Juices with Calcium Helps Decrease the Risk of Dental Erosion Clinical Question In the adult population, does the fortification of calcium to fruit juice reduce enamel erosion as compared to those without calcium? Clinical Bottom Line Results show juices fortified (...) with a calcium compound have the potential to significantly lower the chances of enamel erosion compared to pure juices; however, more evidence is needed to support application clinically. Best Evidence (you may view more info by clicking on the PubMed ID link) PubMed ID Author / Year Patient Group Study type (level of evidence) #1) Scaramucci/2011 80 bovine enamel specimens in various solutions undergoing erosion, demineralization and remineralization. In vitro animal study Key results The specimens

2014 UTHSCSA Dental School CAT Library

99. Impact of coronary artery calcium on coronary heart disease events in individuals at the extremes of traditional risk factor burden: the Multi-Ethnic Study of Atherosclerosis Full Text available with Trip Pro

Impact of coronary artery calcium on coronary heart disease events in individuals at the extremes of traditional risk factor burden: the Multi-Ethnic Study of Atherosclerosis We sought to evaluate the impact of coronary artery calcium (CAC) in individuals at the extremes of risk factor (RF) burden.6698 individuals from the Multi-Ethnic Study of Atherosclerosis (MESA) were followed for coronary heart disease (CHD) events over mean 7.1 ± 1 years. Annualized CHD event rates were compared among (...) the absence of CAC, even among those with many RF, is associated with a low event rate. Coronary artery calcium has the potential to further risk stratify asymptomatic individuals at the extremes of RF burden.Published on behalf of the European Society of Cardiology. All rights reserved. © The Author 2013. For permissions please email: journals.permissions@oup.com.

2014 EvidenceUpdates